Antiretroviral Resistance Testing Comes of Age

Palella F.J. Jr. , Delaney K.M. , Moorman A.C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338: 853–60.

Murray J.S. , Elashoff M.R. , Iacono-Connors L.C. , Cvetkovich T.A. , & Struble K.A. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13: 797–804.

Hirsch M.S. , Conway B. , D'Aquila R.T. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. Journal of the American Medical Association 1998; 279: 1984–1991.

D'Aquila R.T. Limits of resistance testing. Antiviral Therapy 2000; 5: 71–76.

Richman D.D. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Advances in Experimental Medicine & Biology 1996; 394: 383–95.

Richman D.D. Principles of HIV resistance testing and overview of assay performance characteristics. Antiviral Therapy 2000; 5: 27–31.

Hirsch M.S. , Brun-Vezinet F. , D'Aquila R.T. , Hammer S.M. , Johnson V.A. , Kuritzkes D.R. , Loveday C. , Mellors J.W. , Clotet B. , Conway B. , Demeter L.M. , Vella S. , Jacobsen D.M. , & Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society – USA panel. Journal of the American Medical Association 2000; (in press).

Little S.J. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiviral Therapy 2000; 5: 33–40.

DeGruttola V. , Dix L. , D'Aquila R. , Holder D. , Phillips A. , Ait-Khaled M. , Baxter J. , Clevenbergh P. , Hammer S. , Harrigan R. , Katzenstein D. , Lanier R. , Miller M. , Para M. , Yerly S. , Zolopa A. , Murray J. , Patick A. , Miller V. , Castillo S. , Pedneault L. , & Mellors J. The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5: 41–48.

Miller V. , Cozzi-Lepri A. , Hertogs K. , Gute P. , Larder B. , Bloor S. , Klauke S. , Rabenau H. , Phillips A. , & Staszewski S. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antiviral Therapy 2000; 5: 49–55.

Clevenbergh P. , Durant J. , Halfon P. , del Giudice P. , Mondain V. , Montagne N. , Schapiro J.M. , Boucher C.A.B. , & Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antiviral Therapy 2000; 5: 65–70.

Winters M.A. , Baxter J.D. , Mayers D.L. , Wentworth D.N. , Hoover M.L. , Neaton J.D. , & Merigan T.C. Frequency of anti-retroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. Antiviral Therapy 2000; 5: 57–63.

Laessig K.A. , Murray J.S. , & Chikami G. The role of resistance testing in clinical trial design and product labelling: a regulatory perspective. Antiviral Therapy 2000; 5: 77–83.

Schuurman R. , Demeter L. , Reichelderfer P. , Tijnagel J. , De Groot T. , & Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology 1999; 37: 2291–2296.